INTRODUCTION {#s1}
============

Mesothelioma is a rare and aggressive malignancy associated with advanced age and asbestos exposure, that most often arises from the mesothelial lining of the pleura, and less commonly from the peritoneum (7%--30%) ([@MCS003566LUNC23]). It has a poor prognosis with survival ranging from 7 to 27 mo depending on the histological subtype ([@MCS003566LUNC66]). Platinum-based chemotherapy is the first-line treatment for unresectable disease. However, efficacy is often low and disease progression is common ([@MCS003566LUNC41]; [@MCS003566LUNC23]). To improve treatment, increased molecular understanding of the disease is needed, including chemotherapy sensitivity and resistance. We here present a case of a young patient with peritoneal mesothelioma showing an extraordinary chemotherapy response. Using integrative genomic analysis, we aimed to identify genomic drivers and molecular determinants of chemotherapy response, and to suggest potential new therapeutic options.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

The case concerns a 19-yr-old female with no known asbestos exposure, presenting with abdominal pain and cachexia, who in 2013 was diagnosed with disseminated malignant peritoneal mesothelioma, epitheloid subtype ([Figs. 1](#MCS003566LUNF1){ref-type="fig"} and [2](#MCS003566LUNF2){ref-type="fig"}). Routine molecular analysis classified the tumor as *KRAS*, *BRAF*, and *NRAS* wild-type and microsatellite stable. At surgery, the disease was deemed unresectable with a peritoneal cancer index (PCI) of 39, signifying complete involvement of the peritoneal cavity. Palliative chemotherapy (cisplatin-pemetrexed, 10 cycles; carboplatin-pemetrexed, 6 cycles; carboplatin monotherapy 2 cycles) resulted in excellent clinical and radiological response, but treatment had to be discontinued because of allergic reactions. In 2015, laparotomy revealed PCI 16, and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (cisplatin and doxorubicin) was performed. In 2016, lymph node recurrences (aortic and pelvic) were resected, and in 2018, upon radiological progression of a new pelvic recurrence and appearance of a single liver metastasis, rechallenge with carboplatin-pemetrexed was administered, currently with progressive disease. Tumor biopsies and blood samples were obtained following written informed consent at the surgical procedures in 2013 (T1) and 2015 (T2).

![CT images before (T1, PCI = 39) and after (T2, PCI = 16) platinum/pemetrexed chemotherapy.](MCS003566Lun_F1){#MCS003566LUNF1}

![Stained sections of tumor sample before treatment (T1). (*Upper* panel) Hematoxylin and eosin (HE1: 100×, HE2: 200×); (*lower* panel) (100×) the epithelial marker Ber-EP4 (negative) and the mesothelioma marker calretinin (positive).](MCS003566Lun_F2){#MCS003566LUNF2}

Genomic Analyses {#s2b}
----------------

Whole-exome sequencing revealed a total of 121 somatic variants in the T1 and 429 in the T2 tumor sample ([Fig. 3](#MCS003566LUNF3){ref-type="fig"}), representing \>3 times increase in number of mutations. Four and eight known protein-coding cancer-relevant mutations were identified in T1 and T2, respectively ([Table 1](#MCS003566LUNTB1){ref-type="table"}). No cancer-relevant germline mutations were detected.

![Venn diagram and overview of somatic mutations detected in the tumor tissue samples harvested before (T1) and after (T2) chemotherapy. Cancer-relevant mutations include coding variants in known tumor-suppressor genes and proto-oncogenes (coding implies those that alter the protein code or mutations at canonical splice sites). Noncoding mutations refer to silent and nonexonic mutations.](MCS003566Lun_F3){#MCS003566LUNF3}

###### 

Known cancer-relevant mutations (in tumor-suppressor genes and proto-oncogenes) detected in the tumor samples harvested prechemotherapy (T1) and postchemotherapy (T2)

  Gene        HGVS protein         Genomic change       AF pre   AF post   Variant consequence   Predicted effect   dbSNP ID
  ----------- -------------------- -------------------- -------- --------- --------------------- ------------------ ----------
  *LATS2*     p.Val901SerfsTer43   13:g.21553902T\>TC   0.55     0.53      Frame shift           \-                 \-
  *LATS1*     p.Trp879Ter          6:g.149997831C\>T    0.66     0.55      Stop gained           Damaging           \-
  *MECOM*     p.Pro88Ser           3:g.169099088G\>A    0.34     0.19      Missense              Damaging           \-
  *OPCML*     p.Gln49Glu           11:g.132812843G\>C   0.04     \-        Missense              Tolerated          \-
  GATA3^a^    p.Pro189Leu          10:g.8100592C\>T     \-       0.13      Missense              Mixed              \-
  *EPHA3*     p.Gly114Ter          3:g.89259196G\>T     \-       0.15      Stop gained           Damaging           \-
  *GLI1*      p.Cys177Trp          12:g.57859035C\>G    \-       0.04      Missense              Damaging           \-
  *CABLES1*   p.Gln631His          18:g.20837322G\>C    \-       0.03      Missense              Tolerated          \-
  *CASC1*     p.Gly242Ter          12:g.25297577C\>A    \-       0.05      Stop gained           Tolerated          \-
  *ANAPC1*    p.Gln451His          2:g.112615888C\>G    \-       0.04      Missense              Tolerated          79100806

The predicted effect represents the majority prediction of several algorithms included in dbNSFP v3.5. AF, allelic fraction.

^a^Although not considered a proto-oncogene or tumor suppressor per se, we also include the transcription factor GATA3 because of its reported association to breast cancer.

*LATS1/2* were mutated in both samples with an allelic fraction (AF) ∼0.5. These genes encode the large tumor suppressor 1/2 protein kinases and are commonly mutated in pleural and peritoneal mesothelioma ([@MCS003566LUNC42]; [@MCS003566LUNC39]; [@MCS003566LUNC53]; [@MCS003566LUNC63]; [@MCS003566LUNC66]). The stop-gained (*LATS1* p.Trp879Ter), and frame-shift (*LATS2* p.Val901SerfsTer43) mutations are situated in the kinase domains, likely causing loss of protein functions. *MECOM* (MDS1 and EVI-1 complex locus) was also mutated in both samples (AF 0.34 and 0.19). The encoded protein, EVI-1, is a zinc finger transcription factor and oncoprotein involved in cell proliferation ([@MCS003566LUNC15]), functioning as a transcriptional activator, stimulating e.g., *GATA2* and *GATA3* promoters ([@MCS003566LUNC11]). The missense mutation is located in the first zinc-finger domain of the protein, probably affecting DNA binding ([@MCS003566LUNC24]). *GATA3* (GATA binding protein 3) and *EPHA3* (ephrin receptor A3) were mutated only in T2. The transcription factor GATA3 suppresses metastasis through reversal of epithelial-mesenchymal transition (EMT) ([@MCS003566LUNC65]). The missense mutation located in the second transactivating domain of the protein may alter binding to cofactors during transcription. The *EPHA3* gene, encoding a receptor tyrosine kinase, carried a stop-gained mutation in the ligand-binding domain, causing loss of protein function. EPHA3 is involved in cell adhesion, cytoskeleton organization and apoptosis ([@MCS003566LUNC18]).

Similar to the increase of mutations found in T2, copy-number analysis showed a threefold increase in copy-number segments compared to T1 ([Fig. 4](#MCS003566LUNF4){ref-type="fig"}), indicating increased genomic instability. Both samples had heterozygous loss of segments in Chromosome 6 and 13, containing the mutated genes *LATS1*/2, respectively. Additionally, the samples had homozygous loss of a segment in Chromosome 3 containing two important tumor-suppressor genes *BAP1* (BRCA1-associated-protein-1) and *PBRM1* (Protein-polybromo-1), involved in homologous recombination (HR) DNA repair, and chromatin remodeling ([@MCS003566LUNC62]; [@MCS003566LUNC67]). Furthermore, a mutational signature associated with failure of HR repair and response to platinum therapy (S3), was found in T1 and T2 ([Fig. 5](#MCS003566LUNF5){ref-type="fig"}). Two additional signatures (S23 and S24) were present only in T2, exhibiting C\>T and C\>A mutations that most likely are induced by the treatments ([@MCS003566LUNC58]). The tumor mutational burden (TMB) was low (0.87 and 3.82 mutations/Mb in T1 and T2, respectively), consistent with microsatellite stable tumor.

![Copy-number aberration plot from FACETS of samples harvested before (T1) and after (T2) treatment. The chromosomes are depicted with copy-number segments in blue, graded after cellular fraction (cf; dark blue: high cf, light blue: low cf). Heterozygous loss of segments in T1 and T2 were found in Chromosomes 1, 2, 3, 6, 13, and 22, and gains in Chromosome 6 (cf = 0.7). Additionally, T2 had losses in Chromosomes 9, 19, 21, and X, and gains in Chromosomes 1 and 5 (cf = 0.35). The arrows point to homozygous loss in Chromosome 3 (0.3 Mb, cf = 0.7) containing BAP1 and PBRM1, as well as heterozygous loss in Chromosomes 6 and 13 containing LATS1 and LATS2, respectively.](MCS003566Lun_F4){#MCS003566LUNF4}

![Relative contribution of known mutational signatures in T1 and T2. Mutational signatures are different combinations of mutation types generated by different biological processes that improve our understanding of cancer etiology with potential implications for prevention and treatment. Signatures found in both tumor samples were associated with aging (S1), failure of HR DNA repair and responders to platinum treatment (S3). Signatures associated with C\>T mutations (S23) and C\>A mutations (S24) were found only in T2 and are probably related to treatment, whereas a signature of T\>C mutations (S5) was found exclusively in T1. See also <https://cancer.sanger.ac.uk/cosmic/signatures> for a more thorough explanation of the proposed etiologies and associated cancer types underlying each signature.](MCS003566Lun_F5){#MCS003566LUNF5}

Total RNA sequencing was performed on high-quality RNA extracted from T1 (*n* = 3) and T2 samples (*n* = 1). Differential expression analysis revealed 6228 differentially expressed genes, of which 51% were down-regulated after treatment. Among the top up-regulated genes were *AKT3*, a key regulator of the PI3K/AKT/mTOR pathway, *HLA-A* (major histocompatibility complex) that presents antigens to cytotoxic T-cells, the adhesion G-protein coupled receptor G6, and fibronectin (*FN1*), a glycoprotein of the extracellular matrix that binds to integrins in the cell membrane ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003566/-/DC1)). The top down-regulated genes are involved in sodium channels (*SCNN1A* and *SCN9A*), plasma membrane integrity and cytoskeletal structure (*SPTBN2*), cell motility (*SPINT2*), HR DNA repair (*SPIDR*) and regulation of Rho GTPase-activity (*ARHGAP44*) ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003566/-/DC1)). In addition, we found increased expression of mesenchymal markers (e.g., *FN1*) after treatment and reduced expression of epithelial markers ([Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003566/-/DC1)).

Ingenuity pathway analysis (IPA, QIAGEN) was performed with differentially expressed genes as input. The most significantly altered canonical pathways after treatment were related to immune regulation and cancer progression ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003566/-/DC1)). Interleukin signaling and signaling in lymphocytes and macrophages were activated, indicating an increased presence of immune cells in T2. In fact, *CD8*, a marker for cytotoxic T-cells, was threefold up-regulated (*P*~adj~ = 0.03) in T2. The PI3K/AKT/mTOR pathway also showed increased activity through p70S6k and eIF4, supported by deactivation of PTEN signaling, and is consistent with *AKT3* up-regulation. In addition, increased activity of pathways concerning cell adhesion and cytoskeleton organization may indicate altered cell plasticity and motility, which might be related to the mutated *GATA3* and *EPHA3*.

By miRNA sequencing, 139 differentially expressed miRNAs (greater than or equal to twofold change) were identified in T2 compared to T1 (19 up-regulated and 120 down-regulated; [Supplemental Fig. S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003566/-/DC1)). Among the up-regulated miRNAs were miR-29, miR-19, and miR-21 known to target and repress PTEN ([@MCS003566LUNC68]; [@MCS003566LUNC32]; [@MCS003566LUNC60]) and promote EMT ([@MCS003566LUNC14]; [@MCS003566LUNC19]; [@MCS003566LUNC31]). miR-29 is also regulated by GATA3 ([@MCS003566LUNC4]) that was mutated only in the post treatment tumor. Interestingly, a high number of immune-cell specific miRNAs (miR-142 \[[@MCS003566LUNC56]\], miR-155 \[[@MCS003566LUNC8]\], miR-342 \[[@MCS003566LUNC6]\], miR-150 \[[@MCS003566LUNC69]\]) were up-regulated, pointing to an increase of immune cells in T2. Because mir-155 is required for CD8^+^ T-cell responses to cancer, the up-regulation is consistent with increased expression of *CD8* and *HLA-A* in the tumor after treatment.

DISCUSSION {#s3}
==========

Loss-of-function mutations in tumor suppressors *LATS1/2* together with LOH of both genes would leave the tumor cells with only one copy of *LATS1/2*, the majority harboring the mutations. LATS1/2 proteins are involved in the Hippo signaling pathway, which plays an essential role in tissue growth control and is commonly deregulated in cancer ([@MCS003566LUNC12]). Loss of functional LATS1/2 will activate transcriptional coactivators (YAP/TAZ) to promote cell migration, proliferation, and survival ([Fig. 6](#MCS003566LUNF6){ref-type="fig"}; [@MCS003566LUNC36]). The homozygous loss of tumor suppressors *BAP1* and *PBRM1*, found in both tumor samples may also contribute to cancer progression, because defective chromatin remodeling and HR repair over time will give rise to genomic instability ([@MCS003566LUNC59]; [@MCS003566LUNC17]) and increased mutation rate, consistent with the findings in our study. Taken together, *LATS1/2* mutations and loss of *BAP1* and *PBRM1* are likely genomic drivers of the disease.

![Simplified overview of the main pathways (Hippo, PI3K/AKT/mTOR, DNA repair, and chromatin remodeling) affected by the molecular alterations found by integrative genomic analysis in this case of peritoneal mesothelioma. Depicted mutations and copy-number loss (stars) were present in tumor samples before (T1) and after (T2) chemotherapy, whereas components marked up- or down-regulated (triangles) refer to the state in T2 compared to T1.](MCS003566Lun_F6){#MCS003566LUNF6}

In addition to being mutational drivers, the combined loss of *BAP1* and *PBRM1* may explain the observed extraordinary chemotherapy response. HR repair-deficient cancer cells (here due to *BAP1* loss) are not capable of repairing the massive DNA damage caused by chemotherapy and will in most cases undergo cell death. In addition, *PBRM1* loss could further increase sensitivity, because BAF180 (encoded by *PBRM1*) as part of the SWI/SNF complex might play a critical role in protecting DNA from damage ([@MCS003566LUNC9]). The majority of mesothelioma patients harbor *BAP1* alterations with heterozygous loss being detected in about 30%--60% of cases ([@MCS003566LUNC3]; [@MCS003566LUNC2]; [@MCS003566LUNC20]; [@MCS003566LUNC29]; [@MCS003566LUNC16]), whereas homozygous deletion seem to be a rare event in peritoneal mesothelioma and infrequent also in pleural mesothelioma (which is far more extensively studied). However, biallelic inactivation of *BAP1*, which also includes heterozygous deletion combined with an inactivating mutation, seems to be a more common occurrence, and often correlates with loss of BAP1 expression assessed by immunohistochemistry ([@MCS003566LUNC20]; [@MCS003566LUNC29]). It is therefore unlikely that loss of *BAP1* alone could explain the exceptional chemotherapy response in this case. Mutations and homozygous deletions of *PBRM1* are rarely detected in peritoneal mesothelioma, whereas heterozygous deletion is reported at a frequency of 35% ([@MCS003566LUNC2]). Simultaneous complete loss of *BAP1* and *PBRM1* has not previously been described in peritoneal mesothelioma, and seems to be a rare event also in clear-cell renal cell carcinomas in which loss of gene expression of BAP1 and PBRM1 rarely coexist ([@MCS003566LUNC47]). Complete deletion of *PBRM1* alone or in combination with *BAP1* in this case could therefore represent a distinct genotype that could be hypothesized to confer increased sensitivity to DNA damaging agents. Interestingly, in a 2015 case report otherwise very similar to our study, *BAP1* and *PBRM1* aberrations were not detected, and the response to similar treatment was poor ([@MCS003566LUNC53]). The suggested immune response in T2 could also contribute to the therapeutic effect, as it could keep the tumor in a state of functional dormancy ([@MCS003566LUNC38]). Infiltrating CD8-expressing T lymphocytes are associated with improved clinical outcomes in a broad range of tumor types ([@MCS003566LUNC1]).

No standard-of-care is defined in platinum/pemetrexed-resistant peritoneal mesothelioma, and targeted treatments must be considered experimental. Tumors with defective HR repair (i.e., BAP1 loss) may be sensitive to PARP inhibitors ([@MCS003566LUNC33]), and a trial recently opened for use of niraparib in BAP1 deficient cancers, including mesothelioma (NCT03207347), suggesting PARP inhibition as a potential experimental treatment option. Another alternative based on *BAP1* and *PBRM1* deficiency is inhibition of EZH2 (enhancer of zeste homolog 2), the enzymatic subunit of polycomb repressive complex 2 (PRC2) ([@MCS003566LUNC21]; [@MCS003566LUNC40]). The inhibitor exploits synthetic lethality by selectively killing chromatin remodeling-deficient tumor cells that rely on PRC2 for survival ([@MCS003566LUNC40]). A functional dependency of EZH2 activity has been described for *PBRM1* and *BAP1* aberrations in tumors and cell lines, respectively ([@MCS003566LUNC22]; [@MCS003566LUNC25]). The EZH2 inhibitor tazemetostat is being explored clinically, including in *BAP1*-deficient mesothelioma (NCT02860286), indicating that this could be a novel therapeutic possibility. Increased activation of the PI3K/AKT/mTOR pathway in T2 may suggest targeting this commonly deregulated pathway in mesothelioma ([@MCS003566LUNC57]). Clinical benefit was observed for PI3K-mTOR inhibitor apitolisib in two cases of peritoneal mesothelioma ([@MCS003566LUNC7]) and AKT-inhibitors are effective in mesothelioma cell lines ([@MCS003566LUNC64]). Importantly, increased activity in this pathway could explain platinum resistance at rechallenge ([@MCS003566LUNC44]). Immune check-point inhibition is being explored in pleural mesothelioma (NCT03048474, NCT02716272), but in our case the evidence to support such treatment is not conclusive. Low TMB, consistent with the tumor being microsatellite stable, would suggest restricted likelihood of immunotherapy response ([@MCS003566LUNC13]), as would a more mesenchymal phenotype in T2 ([@MCS003566LUNC55]). On the other hand, increased *CD8* expression in T2 could indicate increased cytotoxic T-cell infiltration, which is associated with response to immune checkpoint inhibitors ([@MCS003566LUNC61]; [@MCS003566LUNC55]). A recent study in patients with clear cell renal cell carcinoma showed that loss of functional *PBRM1* was associated with increased overall survival after anti-programmed cell death protein-1 treatment ([@MCS003566LUNC37]). Total loss of *PBRM1* in our case might therefore suggest response to such treatment.

In conclusion, integrative molecular analysis revealed *LATS1/2* as the main mutational drivers of the disease together with total loss of both *BAP1* and *PBRM1*, which also may contribute to the extraordinary chemotherapy response. The molecular profile suggests potential benefit from experimental targeting of PARP, EZH2, the PI3K/AKT/mTOR pathway, and possibly also from immune checkpoint inhibition.

METHODS {#s4}
=======

Patient Samples {#s4a}
---------------

Tumor tissue was harvested at two timepoints, before (T1, *n* = 3) and after (T2, *n* = 1) chemotherapy. The tissue samples were frozen in liquid nitrogen immediately after resection and stored at −80°C. Two HE-stained sections per sample were assessed for tumor content (\>50%) by a pathologist. The tissue samples were homogenized and disrupted using TissueLyzer LT from QIAGEN. DNA/RNA was then extracted from the lysate using the AllPrep DNA/RNA/miRNA Universal Kit automated on the QIAcube (QIAGEN). DNA/RNA concentrations were evaluated using ThermoFisher NanoDrop spectrophotometer and RNA integrity was evaluated by Agilent Technologies Bioanalyzer RNA 6000 Nano kit. All tumor samples had high nucleic acid purity (Abs~260/280~ \>1.8) and RIN values around 9. DNA from EDTA-blood of the patient was used as normal reference for WES-sequencing.

Whole-Exome Sequencing (WES) {#s4b}
----------------------------

WES of DNA from two fresh frozen biopsies and one matching control sample (blood) was performed at the Genomics Core Facility Oslo (Oslo University Hospital, Norway). Library preparation was performed using SureSelectXT Human All Exon V6 + Cosmic (Agilent), following manufacturer\'s instructions. Exome libraries were sequenced paired-end 2 × 100 bp using sequencing by synthesis (SBS) chemistry v3 on an Illumina HiSeq2500. Raw sequencing data was converted to FASTQ files and demultiplexed using the Illumina bcl2fastq v2 software. Sequencing coverage data is presented in [Table 2](#MCS003566LUNTB2){ref-type="table"}.

###### 

Mean coverage data of exome sequencing

  Sample   Mean coverage   \% bases ≥100
  -------- --------------- ---------------
  Normal   170.93          78.4
  T1       245.97          88.8
  T2       233.71          85.4

We applied a bioinformatics pipeline to detect acquired single nucleotide variants and short insertions and deletions in the two tumor samples. Initially, sequence reads of the control sample and the tumor samples were aligned to the human reference genome (build b37 with an added decoy contig) using BWA-mem v0.7.15 ([@MCS003566LUNC30]). Next, marking of duplicates was performed with Picard tools (v.2.5.0); GATK tools (v3.7) were used for two-step local realignment around INDELS (each tumor-normal sample pair was processed jointly), followed by base quality recalibration and calculation of coverage statistics ([@MCS003566LUNC34]). Somatic SNV detection on the two tumor-normal pairs was performed with MuTect and Strelka ([@MCS003566LUNC52]; [@MCS003566LUNC5]). Strelka alone was used for somatic INDEL detection. The total set of somatic variants identified by MuTect and Strelka were further limited to those with a minimum sequencing depth of 20 (both normal and tumor samples). For copy-number detection, we used FACETS, which performs allele-specific copy-number analysis corrected for tumor purity, ploidy, and clonal heterogeneity ([@MCS003566LUNC54]). Finally, we applied the Personal Cancer Genome Reporter ([@MCS003566LUNC43]) an annotation pipeline intended for clinical interpretation of somatic SNVs/InDels and copy-number aberrations, which is built upon a combination of Ensembl\'s Variant Effect Predictor (VEP) and *vcfanno* ([@MCS003566LUNC35]; [@MCS003566LUNC46]). Germline variants (SNVs/InDels) in the control sample were identified using the outlined "Best Practices for Germline SNP & Indel Discovery in Whole Genome and Exome Sequence" developed through GATK/Broad Institute. Specifically, we called germline variants with GATK\'s HaplotypeCaller tool (v3.7) on the existing alignment for the control sample. The variants were subsequently annotated using an in-house developed cancer predisposition report tool (<https://github.com/sigven/cpsr>).

Mutational Signatures {#s4c}
---------------------

We assessed the relative contribution of 30 established mutational signatures (COSMIC) within the somatic base substitution sets of the tumor samples. Specifically, we applied the deconstructSigs framework (PMID:26899170), in which signatures with a weight less than 0.06 were discarded, and the search space per tumor sample were limited to a maximum of six mutational signatures (default settings in v 1.8.0).

RNA Sequencing {#s4d}
--------------

Total RNA sequencing of high-quality RNA from four tumor samples, before (*n* = 3) and after (*n* = 1) chemotherapy, was performed at the Genomics Core Facility Oslo (Oslo University Hospital). RNA sequencing libraries were generated using TruSeq Stranded Total RNA Gold Sample Preparation Kit v2 (Illumina Inc.), and 1 µg total RNA starting material according to the manufacturer\'s instructions. The libraries were quality controlled using Agilent Tape-station for size distribution, and quantified using Agilent qPCR kit for Illumina sequencing libraries. Paired-end sequencing (2 × 75 bp) has been performed on an Illumina NextSeq500 sequencer using v2 chemistry. Raw sequencing data was converted to FASTQ files and demultiplexed using the Illumina bcl2fastq v2 software.

Salmon was used for mapping reads to the reference genome, using default parameters ([@MCS003566LUNC45]). As reference genome, we used the Ensemble annotation based on the genome build GRCh38, found at ftp://ftp.ensembl.org/pub/release-90/fasta/homo\_ sapiens//cdna/Homo_sapiens.GRCh38.cdna.all.fa.gz. To normalize between samples the TMM (trimmed mean of M values) function of the edgeR R/bioconductor package was used on the number of reads per transcript ([@MCS003566LUNC50]; [@MCS003566LUNC49]). To identify transcripts differentially expressed after treatment, we used the voom function of the limma R/bioconductor using default parameters ([@MCS003566LUNC27]; [@MCS003566LUNC48]). Transcripts with Benjamini Hochberg false discovery rate values (*q*-values) less than 0.1 were taken to functional analysis using IPA (QIAGEN Inc., <https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis>). R code can be found at GitHub repository <https://github.com/staaln/mesothelioma>.

smallRNA Sequencing {#s4e}
-------------------

RNA from two tumor samples (before and after treatment) with high quality were used to prepare small RNA NGS libraries (RIN \> 6), using TruSeq Small RNA Library preparation protocol. Successfully prepared libraries were sequenced using Illumina HiSeq 2500 High-Throughput Sequencer using single end sequencing (50 bp).

3′ adapter sequences were automatically identified and trimmed; reads were quality-filtered (Q 33) and reads within length of 18 and 27 nt were retained for mapping using sRNAbench ([@MCS003566LUNC51]), fastx-toolkit and custom perl scripts. Reads were mapped to MirGeneDB ([@MCS003566LUNC10]) using bowtie1.2 ([@MCS003566LUNC26]), requiring an 18 nt seed sequence of zero mismatches to avoid cross-mapping. Mapped reads were counted using "summarizeOverlaps()" function from the "GenomicAlignments" Bioconductor package ([@MCS003566LUNC28]).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

All data that support the findings of this study and that do not compromise research participant privacy are available as [Supplemental Data](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003566/-/DC1). All data that may compromise research participant privacy, subject to GDPR regulations (e.g., raw sequence data), are available for inspection upon request to the corresponding author on nondisclosure terms. The variants have been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession numbers SCV000886625--SCV000886627.
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